Triple attack on kidney cancer: immune booster, radiation, and immunotherapy
NCT ID NCT06601296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immune-boosting drug (IMSA101) and targeted radiation to standard immunotherapy can help control metastatic kidney cancer that has started to grow again. About 15 adults with clear cell kidney cancer that has progressed in up to 5 spots will receive the combination. The goal is to see if this approach can delay the need for stronger treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- New PET scan could reveal kidney cancer drug success in weeks, not months
- New scan could reveal hidden kidney cancer